Novavax Reports Second Quarter 2009 Financi...(9814 General and administrative ...)

Date:8/7/2009

9,814 General and administrative 2,562 3,166 5,454 6,410 ----- ----- ----- ----- Total operating costs and expenses 7,859 8,546 15,017 16,224 ----- ----- ------ ------ Loss from continuing operations before other (expense) income, net (7,830) (8,204) (14,967) (15,424) Other (expense) income, net (710) (110) (1,922) 7 ---- ---- ------ -- Loss from continuing operations (8,540) (8,314) (16,889) (15,417) Loss from discontinued operations - (1,058) - (1,710) -- ------ -- ------ Net loss $(8,540) $(9,372) $(16,889) $(17,127) ======= ======= ======== ======== Basic and diluted net loss per share: Loss per share from continuing operations $(0.10) $(0.14) $(0.22) $(0.25) Loss per share from discontinued operations - $(0.02) - $(0.03) Net loss per share $(0.10) $(0.15) $(0.22) $(0.28) Basic and diluted weighted average number of common shares outstanding 84,832,226 61,329,699 76,806,926 61,286,169 ========== ========== ========== ========== SELECTED BALANCE SHEET DATA (in thousands) As of June 30, As of December 31, 2009 2008 ----
'/>"/>

SOURCE Novavax, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus